. . . "Petr\u00E1kov\u00E1, Katar\u00EDna" . "Mechanisms of tamoxifen resistance"@en . "Klinick\u00E1 onkologie" . . "7"^^ . . "Mechanizmy rezistence na tamoxifen" . . "7"^^ . . "Mechanizmy rezistence na tamoxifen"@cs . . "RIV/00209805:_____/07:#0000004" . . "8"^^ . "20" . . . . "[660FC9F2DD1D]" . "CZ - \u010Cesk\u00E1 republika" . "Endocrine therapy is the most effective systematic treatment for patients with hormone-receptor positive breast cancer. Tamoxifen still represents the most commonly used endocrine treatment. Effi cacy of tamoxifen may be often limited by the onset of resistance. Knowledge on intracellular signal transduction pathways gained in the last years may explain possible mechanisms of tamoxifen resistance. These mechanisms may include loss of expression and/or function of estrogen receptor (ER) or progesterone receptor (PR), alterations in co-regulatory proteins of ER, interferences in signal transduction pathways of growth factor receptors and ER, mutations in tumor suppressor gene p53, the signal transduction pathway PIK3 and alterations in pharmacokinetics of tamoxifen."@en . . "P(NR8270), Z(MZ0MOU2005)" . "RIV/00209805:_____/07:#0000004!RIV08-MZ0-00209805" . "Nenutil, Rudolf" . "0862-495X" . "6" . "Mechanizmy rezistence na tamoxifen" . . . "Hormon\u00E1ln\u00ED l\u00E9\u010Dba je nej\u00FA\u010Dinn\u011Bj\u0161\u00ED syst\u00E9movou l\u00E9\u010Dbou karcinomu prsu pro pacientky s pozitivn\u00EDmi steroidn\u00EDmi receptory. Nejpou\u017E\u00EDvan\u011Bj\u0161\u00ED hormon\u00E1ln\u00ED l\u00E9\u010Dbou v dne\u0161n\u00ED dob\u011B je nad\u00E1le tamoxifen. Jeho \u00FA\u010Dinnost je v\u0161ak \u010Dasto limitovan\u00E1 rezistenc\u00ED n\u00E1dorov\u00FDch bun\u011Bk. Poznatky o intracelul\u00E1rn\u00EDch sign\u00E1ln\u00EDch drah\u00E1ch z\u00EDskan\u00E9 v posledn\u00EDch letech vysv\u011Btluj\u00ED n\u011Bkter\u00E9 mo\u017En\u00E9 mechanizmy vzniku rezistence. Pat\u0159\u00ED k nim ztr\u00E1ta exprese nebo funkce estrogenov\u00E9ho receptoru (ER) nebo progesteronov\u00E9ho receptoru (PR), zm\u011Bny koregula\u010Dn\u00EDch protein\u016F ER, interference sign\u00E1ln\u00EDch drah receptor\u016F r\u016Fstov\u00FDch faktor\u016F a ER, mutace n\u00E1dorov\u00E9ho supresoru p53, sign\u00E1ln\u00ED dr\u00E1ha PIK3 a zm\u011Bna farmakokinetiky tamoxifenu."@cs . "Mechanizmy rezistence na tamoxifen"@cs . "369; 376" . "Mechanisms of tamoxifen resistance"@en . . . "432630" . . "Hormon\u00E1ln\u00ED l\u00E9\u010Dba je nej\u00FA\u010Dinn\u011Bj\u0161\u00ED syst\u00E9movou l\u00E9\u010Dbou karcinomu prsu pro pacientky s pozitivn\u00EDmi steroidn\u00EDmi receptory. Nejpou\u017E\u00EDvan\u011Bj\u0161\u00ED hormon\u00E1ln\u00ED l\u00E9\u010Dbou v dne\u0161n\u00ED dob\u011B je nad\u00E1le tamoxifen. Jeho \u00FA\u010Dinnost je v\u0161ak \u010Dasto limitovan\u00E1 rezistenc\u00ED n\u00E1dorov\u00FDch bun\u011Bk. Poznatky o intracelul\u00E1rn\u00EDch sign\u00E1ln\u00EDch drah\u00E1ch z\u00EDskan\u00E9 v posledn\u00EDch letech vysv\u011Btluj\u00ED n\u011Bkter\u00E9 mo\u017En\u00E9 mechanizmy vzniku rezistence. Pat\u0159\u00ED k nim ztr\u00E1ta exprese nebo funkce estrogenov\u00E9ho receptoru (ER) nebo progesteronov\u00E9ho receptoru (PR), zm\u011Bny koregula\u010Dn\u00EDch protein\u016F ER, interference sign\u00E1ln\u00EDch drah receptor\u016F r\u016Fstov\u00FDch faktor\u016F a ER, mutace n\u00E1dorov\u00E9ho supresoru p53, sign\u00E1ln\u00ED dr\u00E1ha PIK3 a zm\u011Bna farmakokinetiky tamoxifenu." . . "tamoxifen, drug resistance, estrogen receptors, progesterone receptors, Genes HER2, Genes p53"@en . . .